SELLAS Life Sciences Announces Proposed Public Offering of Common Stock
June 26 2018 - 7:46AM
SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) (“SELLAS” or “the
Company”), a clinical-stage biopharmaceutical company focused on
novel cancer immunotherapies for a broad range of cancer
indications, today announced the launch of an underwritten public
offering of 6,075,000 shares of its common stock.
All of the shares in the offering are to be sold by SELLAS. As
part of the offering, SELLAS expects to grant the underwriters a
30-day option to purchase up to an additional 15% of the shares of
common stock offered in the public offering at the public offering
price, less the underwriting discount and commissions. The offering
is subject to market and other conditions and there can be no
assurance as to whether or when the offering may be completed, or
as to the actual size or terms of the offering.
RBC Capital Markets LLC and Cantor Fitzgerald & Co. are
acting as joint book-running managers for the offering. Oppenheimer
& Co. Inc. is acting as lead manager.
A registration statement on Form S-1 relating to the public
offering of the shares of common stock described above has been
filed with the Securities and Exchange Commission ("SEC"), but has
not yet become effective. The shares of common stock may not be
sold nor may offers be accepted prior to the time the registration
statement on Form S-1 becomes effective. This offering is being
made only by means of a prospectus. SELLAS’ SEC filings are
available to the public from the SEC's website at www.sec.gov.
Copies of the preliminary prospectus and final prospectus relating
to the offering may also be obtained, when available, by contacting
RBC Capital Markets LLC, Attention: Equity Syndicate, 200 Vesey
Street, 8th Floor, New York, NY 10281-8098 or by telephone at (877)
822-4089 or by email at equityprospectus@rbccm.com or Cantor
Fitzgerald & Co., Attention: Capital Markets, 499 Park Avenue,
6th Floor New York, New York 10022 or by email at
prospectus@cantor.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or other jurisdiction
in which such offer, solicitation, or sale would be unlawful prior
to the registration or qualification under the securities laws of
any such state or other jurisdiction.
About SELLAS SELLAS is a clinical-stage
biopharmaceutical company focused on novel cancer
immunotherapeutics for a broad range of cancer indications. SELLAS’
lead product candidate, galinpepimut-S (GPS), is licensed from
Memorial Sloan Kettering Cancer Center and targets the Wilms Tumor
1 (WT1) protein, which is present in an array of tumor types.
GPS has potential as a monotherapy or in combination to address a
broad spectrum of hematologic malignancies and solid tumor
indications. SELLAS has Phase 3 clinical trials planned
(pending funding availability) for GPS in two indications, acute
myeloid leukemia (AML) and malignant pleural mesothelioma (MPM) and
is also developing GPS as a potential treatment for multiple
myeloma (MM) and ovarian cancer. SELLAS plans to study GPS in
up to four additional indications. SELLAS has received Orphan
Drug designations for GPS from the U.S. Food & Drug
Administration (FDA) for AML, MPM, and MM, as well as from the
European Medicines Agency, for AML and MPM; GPS also received Fast
Track designation for AML and MPM from the FDA. SELLAS’ second
product candidate, NeuVax™ (nelipepimut-S), is a HER2-directed
cancer immunotherapy being investigated for the prevention of the
recurrence of breast cancer after standard of care treatment in the
adjuvant setting. NeuVax™ has received Fast Track status
designation by FDA for the treatment of patients with early stage
breast cancer with low to intermediate HER2 expression, otherwise
known as HER2 1+ or 2+, following standard of care.
Forward-Looking StatementsThis press release
contains forward-looking statements, including, but not limited to,
statements related to SELLAS’ future expectations, plans and
prospects. These forward-looking statements are based on current
plans, objectives, estimates, expectations and intentions, and
inherently involve significant risks and uncertainties. Actual
results and the timing of events could differ materially from those
anticipated in such forward-looking statements as a result of these
risks and uncertainties, which include, without limitation, risks
and uncertainties associated with market conditions; SELLAS’s
ability to satisfy customary closing conditions related to the
offering; and the volatility of the trading price of the Company’s
common stock. These risks and uncertainties are described more
fully in Amendment No. 1 to Registration Statement on Form S-1
filed with the SEC on June 25, 2018 and other filings with
the Securities and Exchange Commission. Other risks and
uncertainties of which SELLAS is not currently aware may also
affect SELLAS’ forward-looking statements. The forward-looking
statements herein are made only as of the date hereof. SELLAS
undertakes no obligation to update or supplement any
forward-looking statements to reflect actual results, new
information, future events, changes in its expectations or other
circumstances that exist after the date as of which the
forward-looking statements were made.
Investor Contact:Will O’ConnorStern Investor
Relations, Inc.212-362-1200ir@sellaslife.com
David Moser, JDSellas Life Sciences
Group813-864-2571info@sellaslife.com
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Aug 2024 to Sep 2024
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Sep 2023 to Sep 2024